Post

Gilead’s twice-yearly shot prevents 100% of HIV cases in trial with women

Gilead has announced topline results from an interim analysis of its Phase III PURPOSE 1 trial showing that its HIV …

iOnctura raises nearly $86m in Series B to fund Phase II cancer trials

Swiss biopharma iOnctura has raised €80m ($85.8m) in Series B financing to fund the Phase II clinical trials for its …

How improving eConsent can enhance patient retention for clinical trials

As the pharma world embraces digitisation with electronic consent (eConsent) forms, wearable devices, and artificial intelligence enhancing the accuracy of …

Trials to watch: Phase III BCG naïve non-muscle invasive bladder cancer

In 1980, scientists discovered something rather unexpected – the tuberculosis vaccine, Bacillus Calmette-Guérin (BCG) was effective in reducing the recurrence …

NIH Phase Ib/II DLBCL drug combo trial reports 34% complete response

A five drug combination drug therapy trial has shown substantial tumour shrinking in more than half of patients, with some …